ADAMTS Proteinases: Potential Therapeutic Targets?

Author(s): Gavin C. Jones

Journal Name: Current Pharmaceutical Biotechnology

Volume 7 , Issue 1 , 2006

Become EABM
Become Reviewer
Call for Editor


ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) proteinases have been implicated in a number of connective tissue pathologies including Ehlers-Danlos syndrome type VII C, Weill-Marchesani syndrome, encephalomyelitis, and arthritis. These proteinases therefore represent potential therapeutic targets for the treatment of such conditions. The synthesis and activity of ADAMTS proteinases is regulated at multiple levels: transcription, RNA splicing, translation, proteolytic processing, cofactor stimulation and inhibition, each of which represents a possible point of therapeutic intervention. Recent research suggests that, in addition to the direct inhibition of ADAMTS proteinases with low molecular weight non-peptidic inhibitors, targeting the transcription and protein processing of these enzymes could be effective therapeutic approaches.

Keywords: ADAMTS, metalloproteinase, regulation, therapy

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [25 - 31]
Pages: 7
DOI: 10.2174/138920106775789656

Article Metrics

PDF: 13